Analyst Ratings For Cara Therapeutics (NASDAQ:CARA)
Today, Scotiabank lowered its price target on Cara Therapeutics (NASDAQ:CARA) to $32.00 per share.
There are 2 hold ratings, 9 buy ratings on the stock.
The current consensus rating on Cara Therapeutics (NASDAQ:CARA) is Buy (Score: 2.82) with a consensus target price of $26.67 per share, a potential 100.50% upside.
Some recent analyst ratings include
- 7/5/2017-Canaccord Genuity Reiterated Rating of Positive.
- 7/1/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 6/30/2017-Needham & Company LLC Reiterated Rating of Buy.
- 6/30/2017-HC Wainwright Reiterated Rating of Buy.
Recent Insider Trading Activity For Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics (NASDAQ:CARA) has insider ownership of 7.70% and institutional ownership of 52.72%.
- On 7/14/2017 Derek T Chalmers, CEO, sold 25,000 with an average share price of $15.05 per share and the total transaction amounting to $376,250.00. View SEC Filing
- On 7/14/2017 Frederique Ph.D. Menzaghi, VP, sold 3,000 with an average share price of $15.00 per share and the total transaction amounting to $45,000.00. View SEC Filing
- On 6/29/2017 Dean Slagel, Director, sold 250,000 with an average share price of $25.87 per share and the total transaction amounting to $6,467,500.00. View SEC Filing
- On 3/31/2017 Ventures Vi Lp Rho, Major Shareholder, bought 500,000 with an average share price of $18.19 per share and the total transaction amounting to $9,095,000.00. View SEC Filing
- On 4/20/2016 Frederique Ph.D. Menzaghi, VP, sold 6,000 with an average share price of $9.00 per share and the total transaction amounting to $54,000.00. View SEC Filing
- On 3/17/2016 Ventures Vi Lp Rho, Major Shareholder, bought 400,000 with an average share price of $4.87 per share and the total transaction amounting to $1,948,000.00. View SEC Filing
- On 2/3/2016 Frederique Ph.D. Menzaghi, VP, sold 6,000 with an average share price of $9.04 per share and the total transaction amounting to $54,240.00. View SEC Filing
Recent Trading Activity for Cara Therapeutics (NASDAQ:CARA)
Shares of Cara Therapeutics closed the previous trading session at 13.30 up +0.01 0.08% with 1,091,673 shares trading hands.